Abstract
Third-generation tyrosine kinase inhibitor (TKI) osimertinib is standard of care for patients with EGFR-mutant non-small cell lung cancer (NSCLC), although resistance almost inevitably develops. Pelcitoclax (APG-1252) is a dual BCL-2/BCL-xL inhibitor which exhibits synergistic anti-tumor effects with osimertinib in preclinical models of EGFR-mutant NSCLC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
